

1 Seropositivity in blood donors and pregnant women during 9-months of 2 SARS-CoV-2 transmission in Stockholm, Sweden

3

4 Xaquín Castro Dopico^{1#}, Sandra Muschiol², Murray Christian¹, Leo Hanke¹, Daniel J.
5 Sheward¹, Nastasiya F. Grinberg³, Gordana Bogdanovic², Gerald M. Mcinerney¹, Tobias
6 Allander^{1,2}, Chris Wallace^{3,4}, Ben Murrell^{1#}, Jan Albert^{1,2#}, Gunilla B. Karlsson Hedestam^{1#}

7
8 ¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden

9 ²Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden

10 ³Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK

11 ⁴MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 0SR, United Kingdom

12 #Correspondance

13

14 General abstract

15 Public health strategies to contain the pandemic continue to vary markedly across the world.
16 In Sweden, compared to most advanced economies, social restrictions have primarily relied
17 upon voluntary adherence to a set of recommendations and strict lockdowns have not been
18 enforced. To better understand the development of humoral immunity to SARS-CoV-2 in the
19 Stockholm population before the start of mass vaccinations, healthy blood donors and pregnant
20 women ($n=4,100$) were sampled at random between 14th March-11th December 2020. All
21 individuals ($n=200$ /sampling week) were screened for anti-SARS-CoV-2 spike (S) trimer- and
22 RBD-specific IgG responses with highly sensitive and specific ELISA assays, and the results
23 were compared with those from historical controls ($n=595$). Data were modelled using a
24 probabilistic Bayesian framework that considered individual responses to both antigens. We
25 found that after a steep rise at the start of the pandemic, the seroprevalence trajectory increased
26 steadily in approach to the winter second-wave of infections, approaching 15% of all
27 individuals surveyed by 11th December. In agreement with the high transmission rate observed
28 in the Stockholm area, seroprevalence in this cohort of active adults increased during the 9
29 months from the start of the outbreak, but was far from that required for herd immunity at the
30 end of 2020.

31

32 Structured abstract

33 **Objectives:** As Sweden did not enforce social lockdown in response to the pandemic, it is
34 critical to establish seropositivity to SARS-CoV-2 in healthy, active adults – here represented
35 by blood donors and pregnant women. Random sampling was carried out in Stockholm, the
36 country's most populous region, and the study ran from virus emergence (March 2020) until

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 the end of 2020, shortly prior to the first round of vaccinations, allowing for an estimate of
38 population seropositivity in response to natural infection.

39 **Design:** In this cross-sectional prospective study, otherwise-healthy blood donors ($n=2,100$)
40 and pregnant women ($n=2,000$) were sampled at random for consecutive weeks (at three
41 intervals) between 14th March and 11th December 2020. Sera from all participants and a large
42 cohort of historical controls ($n=595$) were screened for IgG responses against the SARS-CoV-
43 2 spike (S) trimer and the receptor-binding domain (RBD). As a complement to standard
44 approaches to analyze the data, a probabilistic Bayesian approach that assigns likelihood of
45 past infection was used to analyze the population data. The study was carried out in accordance
46 with Swedish Ethical Review Authority registration no. 2020-01807.

47 **Setting:** Healthy participant samples were selected from their respective pools at random
48 through the Karolinska University Hospital.

49 **Participants:** None of the participants were symptomatic at the time of sampling and none had
50 previously been hospitalized for COVID-19. No additional metadata was available from the
51 samples.

52 **Results:** Blood donors and pregnant women showed a similar seroprevalence. After a steep
53 rise at the start of the pandemic, the seroprevalence trajectory increased steadily in approach to
54 the winter second-wave of infections, approaching 15% of all individuals surveyed by 11th
55 December 2020. Importantly, 96% of antibody-positive healthy donors screened ($n=56$)
56 developed neutralizing antibody responses at titers comparable to or higher than those observed
57 in clinical trials of SARS-CoV-2 spike mRNA vaccination, supporting that mild infection
58 engenders a competent B cell response.

59 **Conclusions:** In agreement with currently rising COVID-19 cases and ICU occupancy during
60 a second winter wave of infections, these data demonstrate that the metropolitan Stockholm
61 area was far from herd immunity nine months after the outbreak, with approximately one-in-
62 six persons in the examined cohort seropositive for SARS-CoV-2.

63

64 **Introduction**

65

66 Densely populated areas – such as Stockholm county – facilitate the spread of SARS-CoV-2
67 and evidence suggests that transmission can be curtailed by temporary restriction of leisure and
68 business activities, and track and trace¹. In contrast to the vast majority of European, American
69 and Asian countries, Sweden has favored a strategy in which individuals are encouraged to
70 adhere to a set of basic public health instructions, while society has remained largely open –
71 drawing numerous criticisms. The country has reported a significantly higher burden on the
72 healthcare system than its Scandinavian neighbors (Fig. 1A).

73

74 Enumerating past infection status over time is critical for estimating viral spread and
75 understanding characteristics of adaptive immune responses to a new pathogen. Antibody
76 testing is also important for optimal planning of vaccination campaigns, especially when
77 vaccines doses are limited. Therefore, to estimate seropositivity in the capital city, we
78 developed robust SARS-CoV-2 antibody tests and statistical methods and applied them to
79 healthy participants in the region throughout 2020.

80

81 Blood donors and pregnant women, studied throughout, represent two good proxies for adult
82 population health, being generally working age and mobile members of society without being
83 enriched for individuals at especially high-risk of SARS-CoV-2 infection, such as healthcare
84 or public transportation employees, where seroprevalence may be higher. Similarly,
85 seroprevalence may be lower in the unexposed and elderly, and higher in children.

86

87 The data presented here follow seropositivity in across the first and second waves of infections
88 in Stockholm, providing critical information about population immunity over time and prior to
89 the introduction of SARS-CoV-2 vaccines.

90

91

92 **Materials and methods**

93

94 Human samples and ethical declaration

95 Anonymized samples from blood donors ($n=100$ /sampling week) and pregnant women
96 ($n=100$ /sampling week) were randomly selected from their respective pools by the department
97 of Clinical Microbiology, Karolinska University Hospital. No metadata, such as age or sex
98 information were available for the samples in the study. Pregnant women were sampled as part
99 of routine screening for infectious diseases during the first trimester of pregnancy. Blood
100 donors ($n=595$) collected through the same channels a year previously (Spring 2019) were
101 randomly selected for use as assay negative controls. The use of study samples was approved
102 by the Swedish Ethical Review Authority (registration no. 2020-01807) and no study subject
103 was hospitalized for COVID-19 or symptomatic at sample collection. Blood donors are
104 required to be a healthy for a minimum of two weeks before donation.

105

106 Stockholm County death and Swedish mortality data was sourced from the ECDC, EU
107 (<https://www.ecdc.europa.eu/en/covid-19/data>) and the Swedish Public Health Agency
108 (<https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/>), respectively, and
109 were current with the date of publication.

110

111 Serum sample processing

112 Blood samples were collected by the attending clinical team and serum isolated by the
113 department of Clinical Microbiology. Samples were anonymized, barcoded and stored at -20°C
114 until use. Serum samples were not heat-inactivated for ELISA protocols.

115

116 SARS-CoV-2 antigen generation

117 The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain with a
118 C-terminal T4 fibrin trimerization motif was obtained from². The plasmid was used to
119 transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent (Thermo Fisher
120 Scientific). The ectodomain was purified from filtered supernatant on Streptactin XT resin
121 (IBA Lifesciences), followed by size-exclusion chromatography on a Superdex 200 in 5 mM
122 Tris pH 8, 200 mM NaCl. The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned
123 upstream of a Sortase A recognition site (LPETG) and a 6xHIS tag, and expressed in 293F
124 cells as described above. RBD-HIS was purified from filtered supernatant on His-Pur Ni-NTA

125 resin (Thermo Fisher Scientific), followed by size-exclusion chromatography on a Superdex
126 200. The nucleocapsid was purchased from Sino Biological.

127

128 Anti-SARS-CoV-2 ELISA

129 96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S trimers, RBD or
130 nucleocapsid (100 μ l of 1 ng/ μ l) in PBS overnight at 4°C. Plates were washed six times with
131 PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk. Human serum samples were
132 thawed at room temperature, diluted (1:100 unless otherwise indicated), and incubated in
133 blocking buffer for 1h (with vortexing) before plating. Serum samples were incubated
134 overnight at 4°C before washing, as before. Secondary HRP-conjugated anti-human antibodies
135 were diluted in blocking buffer and incubated with samples for 1 hour at room temperature.
136 Plates were washed a final time before development with TMB Stabilized Chromogen
137 (Invitrogen). The reaction was stopped using 1M sulphuric acid and optical density (OD)
138 values were measured at 450 nm using an Asys Expert 96 ELISA reader (Biochrom Ltd.).
139 Secondary antibodies (from Southern Biotech) and dilutions used: goat anti-human IgG (2014-
140 05) at 1:10,000. All assays were developed for their fixed time and negative control samples
141 were run alongside test samples in all assays. Raw 450nm optical density data were log
142 transformed for statistical analyses.

143

144 *In vitro* virus neutralisation assay

145 Pseudotyped viruses were generated by the co-transfection of HEK293T cells with plasmids
146 encoding the SARS-CoV-2 spike protein harboring an 18 amino acid truncation of the
147 cytoplasmic tail²; a plasmid encoding firefly luciferase; a lentiviral packaging plasmid
148 (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was changed 12-16 hours post-
149 transfection and pseudotyped viruses harvested at 48- and 72-hours, filtered through a 0.45 μ m
150 filter and stored at -80°C until use. Pseudotyped neutralisation assays were adapted from
151 protocols validated to characterize the neutralization of HIV, but with the use of HEK293T-
152 ACE2 cells. Briefly, pseudotyped viruses sufficient to generate ~100,000 RLUs were incubated
153 with serial dilutions of heat-inactivated serum for 60 min at 37°C. Approximately 15,000
154 HEK293T-ACE2 cells were then added to each well and the plates incubated at 37°C for 48
155 hours. Luminescence was measured using Bright-Glo (Promega) according to the
156 manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration time of
157 0.3s. The limit of detection was at a 1:45 serum dilution.

158

159 Probabilistic seroprevalence estimations

160 Prior to analysis, each sample OD was standardized by dividing by the mean OD of “no sample
161 controls” on that plate or other plates run on the same day. This resulted in more similar
162 distributions for 2019 blood donor samples with 2020 blood donors and pregnant volunteers.
163 Our Bayesian approach is presented in detail in Christian *et al*³. Briefly, we used a logistic
164 regression over anti-RBD and -S training data (from $n=595$ historical blood donor controls and
165 $n=138$ SARS-CoV-2 PCR+ individuals across the clinical spectrum) to model the relationship
166 between the ELISA measurements and the probability that a sample is antibody-positive. We
167 adjusted for the training data class proportions and used these adjusted probabilities to inform
168 the seroprevalence estimates for each time point. Given that the population seroprevalence
169 cannot increase dramatically from one week to the next, we constructed a prior over
170 seroprevalence trajectories using a transformed Gaussian Process, and combined this with the
171 individual class-balance adjusted infection probabilities for each donor to infer the posterior
172 distribution over seroprevalence trajectories. We validated our Bayesian approach by
173 comparing the output with that of more established probabilistic algorithms (support vector
174 machines and linear discriminant analysis) that we have previously developed for ELISA
175 measurements⁴, finding strong congruency between the approaches.

176 177 **Results**

178
179 Blood donor and pregnant women serum samples ($n=100$ of each per sampling week) were
180 selected at random from their respective pools and the IgG response against SARS-CoV-2 S
181 glycoprotein trimers and the smaller RBD subunit was measured in all sera using established
182 ELISA assays⁴ (Fig. 1B-E). Test samples were run alongside historical (negative) control sera
183 ($n=595$ blood donors from spring 2019) throughout the study.

184
185 Using conventional 3 or 6 standard deviations (SD) from the mean of negative control sera as
186 assay cut-offs for positivity, and simple linear regression, between 17-21% and 14-19% of
187 individuals were IgG-positive against spike or the RBD, respectively, at the last sampling point
188 (11th December) (Fig. 1F).

189
190 However, the many measurements between the 3 and 6 SD cut-offs for both or a single antigen
191 highlight the problem of assigning case to low values. Therefore, to provide an accurate
192 seropositivity estimates for this metric and to model population-level changes over time, we

193 developed and validated a cut-off-independent, probabilistic Bayesian framework that models
194 the log odds a sample is antibody-positive based on responses in training data; in this case
195 SARS-CoV-2 PCR+ COVID-19 patients across the clinical spectrum that we have extensively
196 characterized^{3,4}. The correct classification of low titers is important, since a number of cases
197 that have experienced asymptomatic or mild infection generate antibody titers closer to the
198 assay boundary, and antibody levels decline with time in all seropositive individuals, meaning
199 that incorrect classification can skew seroprevalence estimates⁴⁻⁷.

200

201 Using this more quantitative approach that considers the wide range of responses present in the
202 population and shares information between sampling weeks, we found seropositivity to
203 increase sharply at the start of the pandemic (Fig. 1G). By the time COVID-19 deaths in the
204 country were at very low levels during August, the seroprevalence trajectory increased at a
205 slower rate approaching to the winter second wave (Fig. 1A and G), in agreement with
206 continued viral spread in the Stockholm population, and consistent with persistent antibody
207 responses over a 9-month period.

208

209 By week 50 (11th December), our probabilistic approach identified 14.8% (95% Bayesian CI
210 [12.2-18.0]) of the cohort to have been previously infected (Supp. Table 1). We validated the
211 estimates from our Bayesian approach with an equal-weighted (cut-off-independent) learner
212 from the output of support vector machines and linear discriminant analysis that we previously
213 optimized for ELISA measurements (Fig. 1G)⁴, which showed highly consistent results.

214

215 Importantly, 96% of antibody-positive blood donors and pregnant women randomly sub-
216 sampled from the entire cohort ($n=56$) had virus neutralizing responses in their sera ($ID_{50}=600$;
217 95% CI [357 – 1,010] and $ID_{50}=350$; 95% CI [228 - 538], respectively, Fig. 1H-I), with titers
218 comparable to those engendered by recently-approved COVID-19 mRNA vaccines that were
219 shown to be protective in clinical phase 3 trials^{8,9}. These observations support that
220 asymptomatic/mild infection generates an antibody response that provides a first line of
221 defense against potential re-exposures¹⁰, although inter-individual heterogeneity will have a
222 role in outcomes¹¹⁻¹³.

223

224

225 Discussion

226

227 To characterize immunological responses to SARS-CoV-2 and safeguard public health, it is
228 critical to monitor the level of population immunity after natural infection¹⁴, especially in
229 settings with different public health measures – allowing for concurrent and retroactive
230 evaluation of different strategies. As Sweden has taken a unique public health approach to
231 mitigate the effects of the virus, data from the country provide an important contrast to
232 comparable settings and may help inform future pandemic management.

233

234 Serology is amenable to studies of large cohorts and is the *gold standard* for determining
235 previous exposure to pathogens. Importantly, increasing evidence suggests that most persons
236 infected with SARS-CoV-2 develop virus-specific antibodies, including following mild or
237 asymptomatic infections^{4,15,16}. Studies have highlighted the protective role B cells play in
238 controlling SARS-CoV-2 infection in humans¹⁰ and animal models^{17,18}, while potent
239 neutralizing antibodies were rapidly isolated from infected donor samples^{19–21}. Critical future
240 research is required to determine the duration of B cell memory in those infected, as well as
241 following vaccination. Early results show that infected individuals can maintain a detectable
242 virus-specific B cell response for at least eight months^{20,22}, which together with the steadily
243 increasing seropositivity observed in the study (and in NYC²³), help allay early fears that
244 immunity waned in the short-term; although individuals with mild infection can have titers
245 close to the assay boundary that may decline from peak responses at different rates between
246 individuals. Neutralizing titers in our study samples were comparable to those engendered by
247 the first mRNA vaccines, supporting that natural infection generates immunological memory.
248 Given these observations, antibody testing should be used for optimal coordination of vaccine
249 interventions, especially in the near future when vaccine doses are expected to be limited.

250

251 Epidemiologically, the data presented here indicate that nine months after viral emergence in
252 Stockholm, Sweden – and in the midst of a winter second wave – approximately one-in-six
253 active adults (represented by blood donors and pregnant women) have been infected with the
254 virus. Although this is a considerable number, which is associated with a significant public
255 health burden²⁴, this proportion remains far from that required for herd immunity. This situation
256 in Stockholm is similar to that observed in New York City, USA, where despite high rates of
257 infection and mortality²⁵, herd immunity was not attained within six months of the outbreak,
258 reaching *ca.* 20% of the general population²³. Compared to other European regions, our study

259 supports that Stockholm has fared worse in terms of infections (following the first wave) than
260 the majority of study locations^{26–28}, with the exception of Lombardy, Italy (23% seropositivity,
261 an early European center of infection)²⁹, and comparable to London, UK (13%)³⁰ and Geneva,
262 Switzerland (11%)³¹. However, direct comparisons between sites are complicated by
263 differences in the demographics of the study subjects as well as the sensitivity of the assay used
264 for antibody detection³². Longitudinal studies over longer timescales (first, second and future
265 waves), using robust antibody tests and different cohorts are urgently needed for improved
266 comparisons and understanding COVID-19.

267

268 Together, the results presented here highlight the continued need for measures to curtail virus
269 dissemination and protect the most vulnerable in society. Understanding seroprevalence
270 changes in the population (and individuals) over time - including following the introduction of
271 vaccines - is of fundamental importance for informing public health approaches.

272

273 **Author contributions**

274

275 GKH and XCD designed the study, analyzed the data and wrote the manuscript with input from
276 co-authors. JA, TA, SM and GB provided the study samples. XCD generated the ELISA data.
277 LH, DJS, GM and BM generated SARS-CoV-2 antigens and pseudotyped viruses. DJS
278 performed the neutralization assay. MC, CW, N.F.G, and BM carried out statistical analyses.
279 MC and BM developed the Bayesian framework.

280

281 **Acknowledgments**

282

283 We would like to thank the study participants and attending clinical teams. Funding for this
284 work was provided by a Distinguished Professor grant from the Swedish Research Council
285 (agreement 2017-00968) and the National Institutes of Health, USA (agreement 400
286 SUM1A44462-02) awarded to GKH. CW received funding from the Wellcome Trust
287 (WT107881) and Medical Research Council, UK (MC_UP_1302/5). For the purpose of Open
288 Access, the author has applied a CC BY public copyright licence to any Author Accepted
289 Manuscript version arising from this submission. We thank Joanna Rorbach, for critical reading
290 of the manuscript.

291

292 **Conflict of interest**

293

294 The study authors declare no competing interests related to the work.

295

296 **Data and code availability statement**

297

298 Data generated as part of the study, along with custom code for statistical analyses, is openly
299 available via our GitHub repositories: [https://github.com/MurrellGroup/
300 DiscriminativeSeroprevalence/](https://github.com/MurrellGroup/DiscriminativeSeroprevalence/) and <https://github.com/chr1swallace/seroprevalence-paper>.

301

302 **References**

303

- 304 1. Nicola, M. *et al.* Health policy and leadership models during the COVID-19 pandemic:
305 A review. *International Journal of Surgery* (2020) doi:10.1016/j.ijssu.2020.07.026.
- 306 2. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
307 conformation. *Science* (80-.). (2020) doi:10.1126/science.aax0902.
- 308 3. Christian, M. & Murrell, B. Discriminative Bayesian Serology: Counting Without
309 Cutoffs. *BioRxiv* (2020).
- 310 4. Dopico, X. *et al.* A probability-based approach for identifying low-titer antibody
311 responses against SARS-CoV-2. *Medrxiv* (2020).
- 312 5. Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity
313 and correlates of severity. *Science* (80-.). (2020) doi:10.1126/science.abd4250.
- 314 6. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *British*
315 *Medical Journal* (2006) doi:10.1136/bmj.332.7549.1080.
- 316 7. Cervia, C. *et al.* Systemic and mucosal antibody responses specific to SARS-CoV-2
317 during mild versus severe COVID-19. *J. Allergy Clin. Immunol.* (2020)
318 doi:10.1016/j.jaci.2020.10.040.
- 319 8. Mulligan, M. J. *et al.* Phase I/II study of COVID-19 RNA vaccine BNT162b1 in
320 adults. *Nature* (2020) doi:10.1038/s41586-020-2639-4.
- 321 9. Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report.
322 *N. Engl. J. Med.* (2020) doi:10.1056/nejmoa2022483.
- 323 10. Addetia, A. *et al.* Neutralizing antibodies correlate with protection from SARS-CoV-2
324 in humans during a fishery vessel outbreak with a high attack rate. *J. Clin. Microbiol.*
325 (2020) doi:10.1128/JCM.02107-20.
- 326 11. Jonsson, S. *et al.* Identification of sequence variants influencing immunoglobulin
327 levels. *Nat. Genet.* (2017) doi:10.1038/ng.3897.

- 328 12. Brodin, P. & Davis, M. M. Human immune system variation. *Nature Reviews*
329 *Immunology* (2017) doi:10.1038/nri.2016.125.
- 330 13. Dopico, X. C. *et al.* Widespread seasonal gene expression reveals annual differences in
331 human immunity and physiology. *Nat. Commun.* **6**, 7000 (2015).
- 332 14. Winter, A. K. & Hegde, S. T. The important role of serology for COVID-19 control.
333 *The Lancet Infectious Diseases* (2020) doi:10.1016/S1473-3099(20)30322-4.
- 334 15. Gudbjartsson, D. F. *et al.* Spread of SARS-CoV-2 in the Icelandic Population. *N. Engl.*
335 *J. Med.* (2020) doi:10.1056/nejmoa2006100.
- 336 16. Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-
337 CoV-2 infections. *Nat. Med.* (2020) doi:10.1038/s41591-020-0965-6.
- 338 17. Chandrashekar, A. *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus
339 macaques. *Science* (80-.). (2020) doi:10.1126/science.abc4776.
- 340 18. Deng, W. *et al.* Primary exposure to SARS-CoV-2 protects against reinfection in
341 rhesus macaques. *Science* (80-.). (2020) doi:10.1126/science.abc5343.
- 342 19. Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in
343 Convalescent Individuals. *Nature* (2020) doi:10.1101/2020.05.13.092619.
- 344 20. Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist
345 for months. *Science* (80-.). (2020) doi:10.1126/science.abd7728.
- 346 21. Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*
347 (2020) doi:10.1038/s41586-020-2380-z.
- 348 22. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for greater than
349 eight months after infection. *bioRxiv* (2020).
- 350 23. Stadlbauer, D. *et al.* Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New
351 York City. *Nature* (2020) doi:10.1038/s41586-020-2912-6.
- 352 24. Gémes, K. *et al.* Burden and prevalence of prognostic factors for severe COVID-19 in
353 Sweden. *Eur. J. Epidemiol.* (2020) doi:10.1007/s10654-020-00646-z.
- 354 25. Yang, W. *et al.* Estimating the infection-fatality risk of SARS-CoV-2 in New York
355 City during the spring 2020 pandemic wave: a model-based analysis. *Lancet Infect.*
356 *Dis.* (2020) doi:10.1016/S1473-3099(20)30769-6.
- 357 26. Rostami, A. *et al.* SARS-CoV-2 seroprevalence worldwide: a systematic review and
358 meta-analysis. *Clinical Microbiology and Infection* (2020)
359 doi:10.1016/j.cmi.2020.10.020.
- 360 27. Pollán, M. *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,
361 population-based seroepidemiological study. *Lancet* (2020) doi:10.1016/S0140-

- 362 6736(20)31483-5.
- 363 28. Fischer, B., Knabbe, C. & Vollmer, T. SARS-CoV-2 IgG seroprevalence in blood
364 donors located in three different federal states, Germany, March to June 2020.
365 *Eurosurveillance* (2020) doi:10.2807/1560-7917.ES.2020.25.28.2001285.
- 366 29. Percivalle, E. *et al.* Prevalence of SARS-CoV-2 specific neutralising antibodies in
367 blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.
368 *Eurosurveillance* (2020) doi:10.2807/1560-7917.ES.2020.25.24.2001031.
- 369 30. Ward, H. *et al.* Antibody prevalence for SARS-CoV-2 in England following first peak
370 of the pandemic: REACT2 study in 100,000 adults. *medRxiv* (2020).
- 371 31. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva,
372 Switzerland (SEROCoV-POP): a population-based study. *Lancet* (2020)
373 doi:10.1016/S0140-6736(20)31304-0.
- 374 32. GeurtsvanKessel, C. H. *et al.* Towards the next phase: evaluation of serological assays
375 for diagnostics and exposure assessment. *Nat Comms* **doi: 10.10**, (2020).
376
377




Figure 1: SARS-CoV-2 seropositivity estimates in Stockholm: March-December 2020. (A) Population-adjusted COVID-19 deaths for selected countries during the pandemic. (B) Anti-S IgG responses in blood donors (BD), pregnant women (PW) and $n=595$ historical control sera. 100 BD and 100 PW samples were analyzed per sampling week. Conventional 3 and 6 SD assay cut-offs are shown as dashed and solid lines, respectively. (C) Spike seropositivity in BD and PW according to 3 and 6 SD cut-offs. (D) Anti-RBD IgG responses in blood donors (BD), pregnant women (PW) and $n=595$ historical control sera. Conventional 3 and 6 SD assay cut-offs are shown as dashed and solid lines, respectively. (E) RBD seropositivity in BD and PW according to 3 and 6 SD cut-offs. (F) Seropositivity estimates in BD and PW combined according to 3 and 6 SD cut-offs. Simple linear regression was applied to each estimate. (G) Cut-off-independent Bayesian modelling of population seropositivity. A frequentist, equal-weighted ensemble learner from the output of support vector machines and linear discriminant analysis was used to validate the Bayesian framework. (H) *In vitro* pseudotyped virus neutralizing titers in a subset of antibody-positive BD and PW. Bars represent the geometric mean. (I) Binding and neutralization - for samples in (H) - are highly correlated.